The ‘Brexodus’ begins

BY Richard Summerfield

To date, the UK economy has been surprisingly resistant to Brexit. While in the run up to the referendum some prognosticators forecast that the economy would collapse, and others that the vote would usher in a new era of economic prosperity, with the exception of the fall in the value of sterling, and a recent decline in consumer confidence, nearly a year on from the vote the UK’s economic outlook has remained relatively calm.

One post-Brexit forecast from the pre-election days, however, is coming to pass, with the announcement this week that US financial services mega-power JP Morgan Chase is to move 1000 jobs out of the City of London, relocating them to Dublin, Frankfurt and Luxembourg as part of the firm’s Brexit contingency plans. The UK’s decision to recant from the European Union (EU) was always like to have an impact on the City, given that is the heart of the continent’s financial services sector. By withdrawing from the EU and potentially losing the all-important passporting rights, triggering Article 50 was always going to be transformative. It seems as if several different European cities will now benefit.

“We are going to use the three banks we already have in Europe as the anchors for our operations,” Daniel Pinto, JP Morgan’s head of investment banking, told Bloomberg on Wednesday. “We will have to move hundreds of people in the short term to be ready for day one, when negotiations finish, and then we will look at the longer-term numbers.”

Though JP Morgan is the first firm to solidify its plans, it will not be the only financial services firm fleeing the City. Last week, Richard Gnodde, head of European operations at Goldman Sachs, said his firm would need more people in Madrid, Milan, Paris and other EU centres. Equally, José Viñals, Standard Chartered’s new chairman, told his bank’s AGM that it would be pursuing expansion opportunities in the German city of Frankfurt. “We are looking at setting up a subsidiary in the EU to ensure we’re prepared.”

Deutsche Bank, too, has suggested it could move up to 4000 jobs out of the UK – nearly half its workforce in the country – despite previously maintaining its commitment to the City.

While there is still a great deal of confusion over the Brexit process and the UK’s future relationship with the EU, one thing is becoming very clear – financial services in a post-EU UK will never quite be the same again.

News: J.P. Morgan to Shift Up to 1,000 Jobs Out of London Ahead of Brexit

Air Methods sold to American Securities in $2.5bn deal

BY James Williams

Air medical transport provider Air Methods Corporation and leading US private equity firm American Securities LLC announced that the $2.5bn (including debt) acquisition of Air Methods by American Securities has closed.

As well as being the largest domestic air medical transport provider in the $5bn air medical market (serving 48 states with over 300 bases of operations), Air Methods also operates a leading air tourism business and employs more than 5000 people – including over 1000 retired and active duty military veterans.

With one of the youngest fleets in its industry, which includes its airborne intensive care units (ICUs) dedicated to emergency air medical services, Air Methods provided more than 70,000 patients with lifesaving care last year.

“As a private company, Air Methods will have greater flexibility to execute our strategy and pursue long-term growth,” said Aaron Todd, chief executive of Air Methods. “We look forward to partnering with American Securities to strengthen our market position in air medical transportation and air tourism.”

Acquirer American Securities, based in New York with an office in Shanghai, invests in market-leading North American companies with annual revenues generally ranging from $200m to $2bn and/or $50m to $300m of earnings before interest, tax, depreciation and amortisation (EBITDA). The firm and its affiliates have approximately $15bn under management.

“We have strong admiration for the men and women at Air Methods and their commitment to providing critical access to care for patients and communities served,” commented Marc Saiontz, managing director of American Securities. “The Air Methods team has a paramount focus on clinical care and aviation safety, and on providing hospitals and local communities with the highest quality air ambulance services available. We are excited to assist the company in this critical mission.”

Financial advisers to Air Methods are Goldman Sachs and Centerview Partners LLC, while Paul, Weiss, Rifkind, Wharton & Garrison LLP and Holland & Hart LLP are the company’s legal advisers. Legal adviser to Americana Securities is Weil, Gotshal & Manges LLP.

The Air Methods/American Securities transaction is expected to close by the end of the second quarter of 2017.

News: American Securities completes purchase of medical transport provider Air Methods

Geopolitical uncertainty and buoyant M&A can coexist, says new report

BY Fraser Tennant

Despite ongoing geopolitical uncertainties, companies are continuing to greenlight mergers & acquisitions (M&A) deals in the search for growth, according to EY’s new Global Capital Confidence Barometer.

The Barometer, while recognising that geopolitical concerns are a mainstay feature of the boardroom, notes that such issues are being overshadowed by more immediate and pressing risks and opportunities, with boards increasingly focusing on countermeasures against technological disruption and seizing new routes to growth - countermeasures that often involve M&A transactions.

As a consequence of this focus, the M&A market is currently a healthy environment, with dealmakers expecting further activity in the year ahead.

Among the Barometer’s key findings: (i) 56 percent of companies intend to acquire in the next year; (ii) 73 percent have increased the frequency of the portfolio review process; (iii) 69 percent cite a broad range of geopolitical or emerging policy concerns as the greatest risk to business; (iv) 79 percent of US executives actively plan to pursue deals; (v) 64 percent are looking at cross-border deals to secure market access and grow their customer base; and (vi) 90 percent expect their pipeline to increase or remain stable.

EY also reveals that 97 percent of senior executives expect corporate earnings to accelerate or remain stable, while 64 percent believe that the global economy will improve, despite today’s heightened geopolitical uncertainties.

“While technology and digital disruption are major drivers of the current market, other considerations are also spurring deal activity,” said Steve Krouskos, global vice chair of transaction advisory services at EY. “Geographical expansion to secure supply chains and increase customer reach will accelerate cross-border M&A. Private equity is returning to replenishing mode. Lastly, corporates are increasingly reassessing and reshaping their portfolios, creating a natural pipeline of deal opportunities.”

Sceptics, however, maintain that heightened levels of deal activity are leading to too many bad deals being pursued, a claim that Mr Krouskos dismisses, stating that this is not the case in today’s M&A market. “Companies are using advanced analytics, combined with data-driven diligence and integration, to target the right deals and integrate them in the right way,” he says.

So, can heightened geopolitical uncertainties and buoyant M&A coexist? The answer, says EY, is a resounding yes.

Report: Global Capital Confidence Barometer - Can complex geopolitical uncertainty and record M&A coexist?

Becton and Bard broker $24bn deal

BY Richard Summerfield

US medical technology firm Becton Dickinson has agreed to acquire healthcare equipment manufacturer Bard in a cash and shares deal worth $24bn.

The deal, which is expected to close in the second half of 2017, will see Bard’s common shareholders receive around $222.93 in cash and 0.5077 shares of Becton Dickinson stock per Bard share held, or a total value of $317 per share, based on Becton’s closing price on 21 April, the last working day before the deal was announced. That price represents a 25 percent premium to the Bard share price at the end of last week. In total, Bard shareholders will own around 15 percent of the newly combined company. Becton will fund the deal by borrowing around $10bn, by selling about $4.5bn of equities and equity-linked securities to finance the cash component of the price and by issuing about $8bn in new equity for Bard’s shareholders.

In a statement, Vince Forlenza, Becton’s chairman and chief executive officer, said, “Combining with Bard will accelerate our ability to offer more comprehensive, clinically relevant solutions to customers and patients around the globe, creating a strong partner for healthcare providers who are increasingly focused on delivering better outcomes at a lower total cost. Our two purpose-driven organisations are well-aligned strategically, sharing a strong track record of performance and a deep commitment to addressing unmet needs in today’s challenging healthcare environment. We expect the transaction to contribute meaningfully to BD’s plans for revenue growth and margin expansion, and generate outstanding value both near- and long-term for shareholders.”

The opportunity to expand Becton’s portfolio of brands was too good for the company to pass up, particularly in key foreign markets. Bard is one of the fastest-growing medical technology companies in emerging markets, and the combined company will have annual revenues of about $1bn in China.

Tim Ring, Bard’s chairman and chief executive, said, “We are confident that this combination will deliver meaningful benefits for customers and patients as we see opportunities to leverage BD’s leadership, especially in medication management and infection prevention. We also believe that we can expand our access to customers and patients through BD’s strategic selling capabilities, and that our fast-growing portfolio in emerging markets can significantly benefit from their well-established international commercial infrastructure. Our two companies share the conviction that a product leadership strategy focused on unmet needs and improved outcomes that provide economic value to the global healthcare system will provide long-term shareholder returns.”

News: Becton Dickinson to acquire Bard for $24 billion

Cardinal Health to buy Medtronic units in $6.1bn deal

BY Richard Summerfield

US drug distributor Cardinal Health Inc has agreed to acquire Medtronic PLC’s patient monitoring and recovery unit for $6.1bn in cash. However, reaction to the acquisition has been far from positive, with Cardinal’s share price plummeting in the aftermath of the deal announcement.

According to a statement announcing the deal, Cardinal will fund the acquisition with $4.5bn of new debt and existing cash. The deal structure has proved unpopular, however. Indeed, Fitch Ratings has raised concerns over Cardinal’s debt and, as a result, lowered its outlook on the healthcare services company. In total, Cardinal’s share price fell 13 percent to $71.40.

On the Medtronic side of the transaction, the company is making moves to shed a number of assets in light of its $50bn acquisition of Irish healthcare product manufacturer Covidien in 2015, in a so-called ‘inversion’ deal.

Cardinal will acquire Medtronic’s patient care, deep vein thrombosis and nutritional insufficiency units which will include 23 product categories in total, encompassing multiple market settings, including brands such as Curity, Kendall, Dover, Argyle and Kangaroo.

“Given the current trends in healthcare, including aging demographics and a focus on post-acute care, this industry-leading portfolio will help us further expand our scope in the operating room, in long-term care facilities and in home healthcare, reaching customers across the entire continuum of care,” said Cardinal's chief executive, George S. Barrett, in a statement.

"This is a positive transaction for all involved - Medtronic, Cardinal Health, and our respective shareholders and employees - who we believe will all thrive under this change in ownership. In addition, it signifies our commitment to disciplined portfolio management," said Omar Ishrak, Medtronic's chairman and chief executive officer.

He continued: "Medtronic has had a specific focus over the past several years on ensuring that we are delivering compelling clinical and economic value to health systems and patients around the world. Ultimately, we came to the conclusion that these products - while truly meaningful to patients in need - are best suited under ownership that can provide the investment and focus that these businesses require. At the same time, we can put these proceeds to work, investing over the long-term in higher returning internal and external opportunities that are more directly aligned with our growth strategies of therapy innovation, globalisation, and economic value."

The deal is expected to close in the second quarter of Medtronic's fiscal year 2018, subject to receipt of customary regulatory approvals and satisfaction of other customary closing conditions.

News: Cardinal Health's dull forecast drags rivals' shares despite Medtronic buy